Downing Street Appeal Puts Friedreich’s Ataxia Drug Access Back in Focus
A teenager’s letter to the prime minister has turned a stalled access dispute over omaveloxolone into a public test of how the NHS handles rare neurodegenerative disease. For Brogan Johnson, 17, the issue is not abstract policy. It is a treatment decision tied to a condition that is already affecting her heart, speech, swallowing, mobility and hearing.
Her family says the simple fact that the letter was read by senior political figures brought a measure of relief after months of frustration. The drug in question costs about £1,000 a day to fund privately in the UK, placing it far beyond the reach of most families without a formal NHS route. In a disease with a limited treatment base, that price can function as a near-total barrier rather than a routine access hurdle.
A Rare Disease With Early Systemic Consequences
Friedreich’s ataxia is a progressive neurodegenerative disease with an average life expectancy of 35 to 50 years. The clinical burden extends well beyond gait instability and coordination loss. Brogan’s diagnosis in March 2024 was followed by involvement of multiple organ systems, a reminder that this is not simply a neurological condition of movement alone.
The disease can damage the heart as well as the nervous system, and that combination often drives much of the long-term risk. Swallowing difficulty raises aspiration concerns, while speech and mobility impairment rapidly reduce independence in daily life. Hearing loss adds another layer of disability. In practical terms, every month without effective disease-modifying treatment can mean more accumulated loss across several domains of function.
One family meeting and one letter do not change that biology.
NICE Negotiations Stall as Families Push for a Path Forward
Discussions between Biogen and the National Institute for Health and Care Excellence, the body that evaluates medicines for NHS use, have been paused. NICE has not been able to complete an evaluation of omaveloxolone for use in the UK because Biogen withdrew from the process last year. That leaves families in a difficult position: a medicine exists, patients want it, but the formal pathway that would decide whether the NHS can provide it has been interrupted.
Brogan and her mother, Karly Johnson, delivered their open letter to 10 Downing Street on 13 October. Their MP, David Burton-Sampson, later met Andy Burnham on 26 October to discuss the case. Burton-Sampson said the meeting felt productive and that people’s voices were not being lost in a vacuum. He also said he could not promise a policy shift, while adding that the profile of the issue had been raised and that he planned to speak with health ministers.
A petition on the issue has collected more than 100,000 signatures and is set to be debated in Parliament next year. That level of public response reflects the scarcity of alternatives for families facing a rare disease with a narrowing therapeutic window.
The Drug Debate Now Sits Between Regulation and Urgency
Omaveloxolone, marketed as Skyclarys, sits at the center of a wider clash between regulatory process and patient urgency. The Department of Health and Social Care said NICE had not been able to assess the medicine because Biogen withdrew from the process. The department added that NICE is ready to resume the process if the company returns.
Biogen has pushed back, saying it withdrew because NICE said it would not undertake a full technology appraisal of the medicine. The company also said NICE would have terminated the appraisal anyway, and it expressed an intention to resubmit. Those statements matter because access to rare-disease medicines often depends on whether the manufacturer and assessment body can align on evidence requirements, pricing, and appraisal scope.
For a progressive neurodegenerative condition, delay has a different weight than it does in a stable chronic illness. Disease progression keeps moving while process disputes remain unresolved. In Friedreich’s ataxia, that means more disability can accrue before a formal decision is ever reached.
Interim Care Does Not Replace Disease-Modifying Access
The department said the NHS offers services to manage the condition in the meantime. Supportive care can address symptoms, protect function, and help families navigate the consequences of a degenerative illness. It cannot substitute for a medicine that families believe may alter the disease course itself.
Brogan’s case has become such a visible example because it combines clinical severity with a public-facing access struggle. Her mother described the reading of the letter as a huge relief, and said the family had felt stuck in circles. That language captures a common pattern in rare disease care: repeated contact with institutions, repeated waiting, and no final answer for the patient who is losing time.
The politics of access are now inseparable from the clinical stakes. Friedreich’s ataxia affects only about 1,100 people in the UK, but rarity does not soften the consequences for the individual patient. When a teenager with a progressive neurologic disease is asking for access to a potentially life-changing medicine, the question reaches beyond cost containment. It becomes a test of whether the system can adapt quickly enough for a condition that steadily erodes function while paperwork advances at a crawl.
Parliament Now Faces a Narrow Question
The upcoming parliamentary discussion will not decide whether omaveloxolone works; it will determine whether the UK system can complete the appraisal needed to judge whether it should be available on the NHS. NICE says it is ready to restart. Biogen says it wants to resubmit. The family wants the drug accessible before more irreversible decline sets in.
For now, the central clinical fact remains unchanged: Brogan has a progressive neurodegenerative disease with cardiac and neurological involvement, and the potential route to treatment in the UK is still suspended between institutional positions. The delay itself has become part of the story, and for families facing Friedreich’s ataxia, that delay is measured in function, not headlines.